Clinical Trials on Appendiceal Mucinous Neoplasm in Finland

Total 2478 results

Helsinki University Central Hospital

Completed

SpyGlass in Preoperative Diagnostics of Presumed Main Duct IPMNs: Efficacy and Novel Insights on Complications

Intraductal Papillary Mucinous Neoplasm

Sweden, Finland
Turku University Hospital
University of Helsinki

Recruiting

Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC (DECIDER)

High Grade Serous Carcinoma | High Grade Ovarian Serous Adenocarcinoma

Finland
Aromtech Ltd.
The Finnish Funding Agency for Technology and Innovation

Completed

Effects of Sea Buckthorn Oil on Mucous Membranes (SBMM)

Mucous Membranes

Finland
National Cancer Institute (NCI)
NRG Oncology

Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7

United States, Canada, Israel, Belgium
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Endometrial...

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States, Japan
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Nausea and Vomiting | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Stage IIA Fallopian Tube Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Lynch Syndrome | Colon Mucinous Adenocarcinoma | Colon Signet Ring Cell Adenocarcinoma | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7

United States, Canada, Puerto Rico, Peru, South Africa
Tampere University Hospital

Completed

Does Bloody Urine Predict Urethrovesical Anastomosis Leakage After Radical Prostatectomy

Prostatic Neoplasm | Anastomosis

Finland
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Cavity Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian...

United States
Tampere University Hospital

Active, not recruiting

Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

Colorectal Cancer | Residual Disease

Finland
GOG Foundation
National Cancer Institute (NCI)

Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Helsinki University Central Hospital

Recruiting

Pre- vs. Postoperative Thromboprophylaxis in Pancreatic Surgery (PREPOSTEROUS2)

Thrombosis | Bleeding | Surgery | Pancreas Cancer | Pancreas Neoplasm

Finland
Turku University Hospital

Completed

Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute (BAGvsTCP)

Bone Neoplasm

Finland
Brown University
Pfizer; Lifespan

Terminated

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Ovarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous Carcinoma

United States
Turku University Hospital

Recruiting

99mTc-MIP-1404 SPECT/CT in Primary Staging of Prostate Cancer

Prostate Cancer

Finland
Turku University Hospital
Nordic Urothelial Cancer Group

Recruiting

Nordic Cystectomy Study II - Albumin (NorCys-Alb)

Bladder Cancer | Invasive Bladder Cancer

Finland
Turku University Hospital
Nordic Urothelial Cancer Group

Recruiting

Nordic Cystectomy Study III - Transfusion (NorCys-Transf)

Bladder Cancer | Invasive Bladder Cancer

Finland
Turku University Hospital
Nordic Urothelial Cancer Group

Recruiting

Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR) (NorCys-NLR)

Bladder Cancer | Invasive Bladder Cancer

Finland
Turku University Hospital

Unknown

Improved Prostate Cancer Diagnosis - Combination of Rapid Prebiopsy Magnetic Resonance Imaging and Biomarkers (IMPROD2_0)

Prostate Cancer

Finland
Turku University Hospital

Recruiting

Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer (NeoADT-TULSA)

Prostate Cancer | Localized Prostate Carcinoma | Intermediate Risk Prostate Cancer | Castration-Naive Prostate Cancer

Finland
Helsinki University Central Hospital
University of Helsinki; Tampere University; Tampere University Hospital; Finnish...

Active, not recruiting

Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death (SuddenDeath)

Primary Aldosteronism | Pheochromocytoma | Adrenal Cushing Syndrome | Endocrine Neoplasia

Finland
Gynecologic Oncology Group
Novartis

Active, not recruiting

Ribociclib and Letrozole Treatment in Ovarian Cancer

Low Grade Serous Carcinoma

United States
Patricia I. Dickson, M.D.
University of California, Los Angeles; FDA Office of Orphan Products Development and other collaborators

Terminated

Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

Mucopolysaccharidosis I | Lysosomal Storage Diseases | Spinal Cord Compression

United States, Finland
Tampere University
Finnish Cultural Foundation; Sigrid Jusélius Foundation; Päivikki and Sakari... and other collaborators

Recruiting

HaemoDYNAMICs in Primary and Secondary Hypertension (DYNAMIC)

Renal Insufficiency | Aortic Stenosis | Primary Hypertension | Secondary Hypertension

Finland
Helsinki University Central Hospital

Active, not recruiting

Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery (MOBILE2)

Colorectal Neoplasms | Colorectal Cancer | Surgery--Complications | Surgical Site Infection | Colorectal Carcinoma | Rectal Adenocarcinoma | Rectum Neoplasm | Rectum Carcinoma

Finland
Avenge Bio, Inc

Terminated

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Primary Peritoneal Carcinoma | Neoplasm, Ovarian | Adenocarcinoma Ovary | Serous Adenocarcinoma of Ovary | Serous Adenocarcinoma of Primary Peritoneum | High Grade Serous Adenocarcinoma

United States
University of Oulu

Completed

APEMESH II - Perineal Reconstruction

Rectal Cancer

Finland
Tampere University Hospital

Completed

Colon Cancer Surgery in the Aged; Postoperative Outcome, Functional Recovery and Survival.

Colon Cancer

Finland
Turku University Hospital
GE Healthcare; Blue Earth Diagnostics

Completed

Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI (Flucipro)

Prostate Carcinoma

Finland
University of Oulu
Oulu University Hospital

Terminated

Protection of Rectum From High Radiation Doses Using a Spacer

Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms

Finland
Boneca Corporation

Completed

BNCT to Treat Glioma That Has Progressed Following Radiotherapy

Glioblastoma | Anaplastic Astrocytoma

Finland
Blue Earth Diagnostics

Completed

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Prostate Cancer

Finland
Turku University Hospital

Unknown

The Effect of ADT on PSMA-PET. (ADTPSMA)

Prostate Cancer

Finland
Lidds AB

Completed

An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate (2-HOF)

Prostate Cancer

Finland
University of Oulu
Oulu University Hospital

Completed

Protection of Rectum From High Radiation Doses

Prostate Cancer

Finland
Tampere University

Completed

Casodex/Zoladex Biomarkers in Localised Prostate Cancer

Prostate Cancer

Finland
Pia Osterlund

Recruiting

A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland (RAXO)

Metastatic Colorectal Cancer

Finland
Faron Pharmaceuticals Ltd

Withdrawn

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (RENACOL)

Carcinoma, Renal Cell | Carcinoma Colon

Finland
Turku University Hospital

Terminated

Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT (RESCORE)

Colorectal Cancer

Finland
University of Helsinki
Turku University Hospital; Oulu University Hospital; Kuopio University Hospital; Tampere University Hospital and other collaborators

Recruiting

PErsonalized TReatment for Endometrial Carcinoma (PETREC)

Endometrial Adenocarcinoma

Finland
University of Helsinki
Helsinki University Central Hospital

Unknown

The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy

Thyroid Neoplasms

Finland
Turku University Hospital

Completed

Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT (DOTAGLI)

Glioma

Finland

Clinical Trials on Appendiceal Mucinous Neoplasm in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations